<DOC>
	<DOCNO>NCT00971685</DOCNO>
	<brief_summary>Lenalidomide immunomodulatory drug derive thalidomide , without neurotoxicity . Lenalidomide block increase secretion interleukin-6 , tumor necrosis factor alpha vascular endothelial growth factor ( VEGF ) . The association dexamethasone increase Lenalidomide response rate . More recently efficacy Lenalidomide report patient POEMS ( POEMS : polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy , skin change ) syndrome improvement clinical condition reduction vascular endothelial growth factor ( VEGF ) interleukin-6 ( IL-6 ) level .</brief_summary>
	<brief_title>The Treatment Lenalidomide Patients With POEMS Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>POEMS Syndrome</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients diagnosis POEMS syndrome base publish diagnostic criterion Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>